

**Sawai Pharmaceutical to Construct New Solid Dosage Form Facility
Within Daini Kyushu Factory**

Name	Sawai Group Holdings Co., Ltd. (Securities Code: 4887)
Overview	Sawai Pharmaceutical decided to newly construct a solid dosage form facility at the site of Daini Kyushu Factory.
Purpose	The purpose of the new construction is to respond to the increase in demand for the company's products due to issues related to quality, supply, etc. regarding the generic drug industry as of late, as well as to strengthen production capacity in response to further market expansion of generic drugs in the future.
Details	To the current annual production capacity of 2.5 billion tablets at the factory, an annual production capacity of 2 billion tablets will be added in 2024 as a first step, and a production capacity of 1 billion tablets will be added promptly thereafter upon taking into consideration market trends, the company's new drug development conditions and other factors. This is part of an initiative to establish a production capacity of over 20 billion tablets at an early stage as indicated in the medium-term management plan, and this large-scale investment will increase the production capacity of Sawai Pharmaceutical by about 20% from the current 15.5 billion tablets. Sawai Pharmaceutical will also proactively promote facility enhancement as well as securement of personnel toward increasing production at its Sanda factory and other factories in order to increase production capacity in stages and achieve a production capacity of over 20 billion tablets.
Inquiries	Group Public Relations & Investor Relations Office, Sawai Group Holdings Co., Ltd. E-mail: ir@sawai.co.jp URL: https://global.sawaigroup.holdings

Disclaimer: Corporate Flash is a service provided by Transpacific Enterprises as part of Japan Market Flash services. Any inquiries concerning the content of the posted information should be made directly to the contact at the concerned company. The information provided herein does not constitute business, legal, investment or tax advice, and is presented without any representation or warranty whatsoever as to the accuracy or completeness of the information, or whether it reflects the most current developments. Parties seeking advice should consult with business, legal, investment or tax counsel familiar with their particular circumstances. The sole purpose of this service is to provide information for the users of the service, and is not to solicit investment, or to recommend an investment in a specific issue, etc.